Roche provides update on tominersen programme in manifest Huntington’s disease
Dosing to stop in Phase III clinical study of tominersen following recommendation from an Independent Data ...
Read moreDosing to stop in Phase III clinical study of tominersen following recommendation from an Independent Data ...
Read moreAddress: | Pharma Reg News, First floor, Shop no.1 , Plot no 241,242, Near Fire station, GIDC, Ankleshwar, Gujarat - 393002. |
Phone: | +91 8511586232, +91 9029066605 |
Email: | author@pharmaregnews.com |
© 2021 - Pharmaregnews.com. Developed by YESWEUS.
© 2021 - Pharmaregnews.com. Developed by YESWEUS.